Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-18 + glycoprotein 100 dendritic cell vaccine
- Development stage
- Preclinical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**interleukin-18 + glycoprotein 100 dendritic cell vaccine** is an experimental cancer immunotherapy that combines *interleukin-18* (IL-18), an immunostimulatory cytokine, with the melanoma-associated antigen *glycoprotein 100* (gp100), delivered via autologous dendritic cells. The vaccine is produced by modifying tumor cells to express IL-18 and incorporating gp100 antigen, then generating dendritic cells pulsed with exosomes from these modified tumor cells. This strategy is designed to enhance dendritic cell maturation, increase the expression of co-stimulatory molecules, and potentiate anti-tumor immune responses—specifically the induction of gp100-specific cytotoxic T lymphocytes (CTLs). Mechanistically, IL-18 acts as a Th1-promoting cytokine that stimulates T cell activation, while dendritic cells present gp100 antigen to provoke specific anti-tumor immunity. The approach aims to improve the efficacy of dendritic cell vaccines for melanoma and other cancers over conventional exosome or antigen vaccines[1].
- Other names
- IL-18 + gp100 dendritic cell vaccineIL-18 gene-modified tumor exosome-pulsed dendritic cell vaccineIL18 gene-modified tumor exosome-pulsed dendritic cell vaccineIL 18 gene-modified tumor exosome-pulsed dendritic cell vaccine
02
Targets
IL-18R (Interleukin-18 receptor complex)PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on interleukin-18 + glycoprotein 100 dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-18 + glycoprotein 100 dendritic cell vaccine.